Industry
Biotechnology
Cingulate Inc., a clinical-stage biopharmaceutical company, focuses on the development of product candidates for the treatment of attention-deficit/hyperactivity disorder. The company's lead product candidates are CTx-1301 (dexmethylphenidate), which is in phase 3 clinical trial, and CTx-1302 (dextroamphetamine) for the treatment of attention-deficit/hyperactivity disorders. It also focuses on developing CTx-2103 for the treatment of anxiety disorders. The company was founded in 2012 and is headquartered in Kansas City, Kansas.
Loading...
Open
N/A
Mkt cap
N/A
Volume
N/A
High
N/A
P/E Ratio
N/A
52-wk high
N/A
Low
N/A
Div yield
N/A
52-wk low
N/A
Portfolio Pulse from Benzinga Newsdesk
November 28, 2023 | 2:26 pm
Portfolio Pulse from Benzinga Newsdesk
November 13, 2023 | 10:36 pm
Portfolio Pulse from Benzinga Insights
November 06, 2023 | 9:31 pm
Portfolio Pulse from Benzinga Insights
October 13, 2023 | 9:31 pm
Portfolio Pulse from Benzinga Newsdesk
September 26, 2023 | 10:27 am
Portfolio Pulse from Lisa Levin
September 19, 2023 | 12:49 pm
Portfolio Pulse from Lisa Levin
September 12, 2023 | 12:00 pm
Portfolio Pulse from Vandana Singh
September 11, 2023 | 5:17 pm
Portfolio Pulse from Bill Haddad
September 11, 2023 | 1:23 pm
All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.